From Discovery
to Impact

Our mission is to develop breakthrough preventive therapies that defend against the growing threat of synthetic drugs. By combining advanced immunotherapy, AI-driven discovery, and strategic partnerships, we’re focused on building a safer future for individuals, families, and communities. More details on our formulation outlined to the right.

*For illustration purposes only. Not an approved FDA product. All claims are based on preclinical data.

01 Hapten

Works with the body to specify fentanyl as the bad actor in the body - preparing to mount a protective response.

Specific to fentanyl without interfering with other pain medications or OUD treatments. Shown to be safe and effective in multiple animal species.

02 Carrier Protein

Makes the immune system aware of fentanyl in the body allowing for a protective response.

Already on the market in seven approved treatments.

03 Adjuvant

Amplifies the immune response to bolster sustained and robust protection.

Previously vetted for safety in >2000 adults and hundreds of children. More than 100 pre-clinical and clinical studies.

Research & Development

Discover the science behind our platform. How we go from drug threat identification to potential drug threat solution.

Expansion on the Horizon

Plans to expand into multivalent formulations, oral and intranasal dosing, complementary antibody and small molecule programs.

Platform Technology

Our proprietary platform is built to be adaptable. Being designed to provide multiple solutions against current and emerging drug threats, starting with fentanyl as our first target.

Safety & Transparency First

ARMR Sciences’ platform uses well established, naturally derived components and contains no metals, aluminum, mercury, or thimerosal.

A Platform Approach is Critical to End the Crisis

Today’s crisis won’t be solved with yesterday’s solutions. We are building a pipeline designed to evolve with the changing synthetic drug landscape, creating new preventive technologies where no solutions currently exist.

Emerging Threats

Learn about our current clinical studies, including eligibility, study design, and development progress.

Threat 01

Carfentanil

  • 100x More potent than fentanyl.
  • +720% Increase in carfentanil-involved overdose deaths from January–June 2023 (29 deaths) to January–June 2024 (238 deaths).
  • 37 States Carfentanil was detected in overdose deaths across 37 U.S. states during January 2023–June 2024.
Threat 02

Nitazenes

  • 2,000× More potent than morphine (depending on the specific nitazene compound).
  • 2019 First emerged in the illicit North American drug supply, with detections increasing rapidly since then.
  • 400+ Deaths The UK reported more than 400 nitazene-related overdose deaths over an 18-month period through January 2025.
Threat 03

Medetomidine

  • 87% Detected in 87% of fentanyl drug samples in Philadelphia as of January 2025. 
  • 200× Approximately 200 times more potent than xylazine.
  • 2022 First identified in the illicit opioid supply in North America and now spreading to multiple states.